Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNPAT | O15228 | 1/20 | 0.52 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.51 |
| ▸ | NPY4R | P50391 | 10/20 | 0.49 |
| ▸ | NPY1R | P25929 | 7/20 | 0.49 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.49 |
| ▸ | NPY2R | P49146 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12285427 | 1.00 | GNPAT (0.52) | GNPATKISS1RNPY4RNPY1RNPY5R | |
| SCHEMBL24488479 | 0.94 | NPY4R (0.51) | GNPATKISS1RNPY4RNPY1RNPY5R | |
| SCHEMBL24488464 | 0.91 | NPY4R (0.49) | KISS1RNPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL12286269 | 0.90 | NPY4R (0.48) | NPY4RNPY1RNPY5RNPY2RNPC1 | |
| SCHEMBL12285389 | 0.89 | NPY4R (0.52) | NPY4RNPY1RNPY5RNPY2RNPC1 | |
| SCHEMBL12099664 | 0.89 | NPY4R (0.52) | NPY4RNPY1RNPY5RNPY2RNPC1 | |
| SCHEMBL21464838 | 0.89 | NPY4R (0.49) | NPY4RNPY1RNPY5RNPY2RNPC1 | |
| SCHEMBL21464836 | 0.89 | NPY4R (0.49) | NPY4RNPY1RNPY5RNPY2RNPC1 | |
| SCHEMBL30045851 | 0.89 | KISS1R (0.61) | GNPATKISS1RNPY4RNPY1RNPY5R | |
| SCHEMBL24040280 | 0.88 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2RNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11400062-B2 | Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2022-08-02 | — | — | US | disclosed |
| US-20120232066-A1 | COMPOSITIONS FOR REDUCING RISK OF ADVERSE EVENTS CAUSED BY DRUG-DRUG INTERACTIONS | SIGNATURE THERAPEUTICS, INC. | 2012-09-13 | — | — | US | disclosed |
| WO-2011133348-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF | PHARMACOFORE, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133347-A1 | COMPOSITIONS COMPRISING TRYPSIN-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF | PHARMACOFORE, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232066-A1 | COMPOSITIONS FOR REDUCING RISK OF ADVERSE EVENTS CAUSED BY DRUG-DRUG INTERACTIONS | CYP2C19, CYP3A5, CYP3A4 | GNPAT 1687/4885KISS1R 2937/4885NPY4R 2127/4885 |
| US-11400062-B2 | Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof | ACHE, COMT, CES2 | GNPAT 369/4885KISS1R 4132/4885NPY4R 2732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.